Broader health care exchange traded funds have are rebounding from the late first quarter/early second quarter declines brought on by the biotechnology sell-off.

The health care sector, the S&P 500’s third-largest sector weight behind technology and financial services, remains fundamentally sound, but investors may want to temper expectations of out-sized near- to medium-term gains.

“Profit growth it is forecast to rebound this year on better-than-usual sales growth. However, P/E multiples have risen considerably over the last two years as the Health Care sector has been revalued by investors, and multiples now exceed their pre-crisis levels. Higher share prices have in turn diminished the sector’s attractiveness to slightly below average in our opinion,” said AltaVista Research in a new research note.

Valuation is not an unfamiliar concern facing health care stocks and the relevant exchange traded funds. In February, several weeks before the biotech sell-off started in earnest, the Health Care Select Sector SPDR (NYSEArca: XLV) was seen sporting a P/E ratio slightly in excess of the Consumer Staples Select Sector SPDR (NYSEArca: XLP). [Health Care ETFs Dealing With High Valuations]

That was the first time in eight years health care stocks were more expensive than staples. Although it was not among the nearly 220 ETFs that hit new 52-week highs Monday, XLV, the largest health care ETF, is higher by nearly 4% over the past month. The ETF closed at $59.87 Monday, just 63 cents below its 52-week high.

AltaVista rates XLV neutral, indicating average appreciation potential. That is the rating the research firm assigns to the bulk of the 800 ETFs in its coverage universe.

Showing Page 1 of 2